Imatinib Viatris (Imatinib)

Imatinib blocks the ATP‑binding sites of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases. By preventing these enzymes from phosphorylating downstream proteins, the drug stops the signaling pathways that promote malignant cell proliferation, induces apoptosis, and reduces tumor angiogenesis.

The dose of Imatinib Viatris is individualized by the treating physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and any concomitant medications. Only a qualified prescriber can determine the appropriate dosing regimen.

Imatinib is classified as pregnancy category unknown, and animal studies have shown potential fetal risk. It should only be used during pregnancy if the potential benefit justifies the risk. Breastfeeding is not recommended because the drug is excreted in milk and could affect the infant.

To place an order, submit an enquiry on the Imatinib Viatris product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imatinib was the first targeted tyrosine‑kinase inhibitor approved for chronic myeloid leukemia and remains a standard first‑line option. Compared with newer agents such as dasatinib or nilotinib, imatinib has a well‑characterized safety profile and extensive long‑term data, though some newer drugs may offer faster molecular responses in certain patients.

Imatinib Viatris should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Imatinib Viatris is taken orally, usually once daily, with a glass of water. It may be taken with or without food, but consistent administration with respect to meals helps maintain stable drug levels. Patients should swallow the tablet whole and not crush or chew it.

Serious adverse events include severe neutropenia or thrombocytopenia, hepatotoxicity, cardiac failure, pulmonary arterial hypertension, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should report any signs of infection, jaundice, shortness of breath, swelling, or severe rash to their healthcare provider promptly.

Imatinib Viatris is contraindicated in patients with known hypersensitivity to imatinib or any of its excipients. Caution is advised for individuals with pre‑existing severe liver impairment, uncontrolled cardiac disease, or those taking strong CYP3A4 inhibitors without dose adjustment. Pregnant or nursing women should only use it if clearly needed and after consulting a specialist.